Literature DB >> 19276358

Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.

Christopher M Long1, Hanneke W M van Laarhoven, Jeff W M Bulte, Hyam I Levitsky.   

Abstract

A major parameter limiting immune responses to vaccination is the number of activated antigen-presenting cells (APC) that capture antigen and migrate to draining lymph nodes (LN). Currently, a quantitative noninvasive technique for monitoring in vivo antigen capture and delivery is lacking. The use of cellular magnetic resonance (MR) imaging (MRI) is a promising approach for this purpose; however, cellular imaging currently requires ex vivo prelabeling of cells with contrast agents followed by reintroduction of cells into the subject being monitored. Here, we describe an in vivo labeling method, which relies upon cell-to-cell transfer of superparamagnetic iron oxide (SPIO) from tumor cells to endogenous APCs, in situ, to quantify APC delivery to LNs in a tumor vaccine model. Mice were immunized with a tumor cell-based vaccine that was irradiated and labeled with SPIO. APCs that had captured SPIO were imaged over time as they accumulated in LNs. We show here that MRI is capable of monitoring, in vivo, the trafficking of magnetically labeled APCs inducing a tumor-specific immune response, and that these cells can be magnetically recovered ex vivo. Excellent correlation was observed between in vivo and ex vivo quantification of APCs, with resolution sufficient to detect increased APC trafficking elicited by an adjuvant. This study shows the potential of magnetovaccination and MRI cell tracking to systematically evaluate a key parameter relevant to the optimization of vaccine therapies through noninvasive MRI-based quantification of APC numbers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276358      PMCID: PMC3031988          DOI: 10.1158/0008-5472.CAN-08-3691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging.

Authors:  Jeff W M Bulte; Ali S Arbab; T Douglas; J A Frank
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

Review 2.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

3.  In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.

Authors:  A Y Huang; A T Bruce; D M Pardoll; H I Levitsky
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

4.  Tumor-specific Th17-polarized cells eradicate large established melanoma.

Authors:  Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas C Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Journal:  Blood       Date:  2008-03-19       Impact factor: 22.113

5.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

7.  Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation.

Authors:  Smita Nair; Catherine McLaughlin; Alon Weizer; Zhen Su; David Boczkowski; Jens Dannull; Johannes Vieweg; Eli Gilboa
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

8.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Authors:  A Y Huang; P Golumbek; M Ahmadzadeh; E Jaffee; D Pardoll; H Levitsky
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

9.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

10.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.

Authors:  H I Levitsky; A Lazenby; R J Hayashi; D M Pardoll
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  43 in total

1.  Long-term MR cell tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells.

Authors:  Stacey Cromer Berman; Chulani Galpoththawela; Assaf A Gilad; Jeff W M Bulte; Piotr Walczak
Journal:  Magn Reson Med       Date:  2010-10-06       Impact factor: 4.668

2.  In vivo cellular MRI of dendritic cell migration using micrometer-sized iron oxide (MPIO) particles.

Authors:  Roja Rohani; Sonali N de Chickera; Christy Willert; Yuhua Chen; Gregory A Dekaban; Paula J Foster
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

3.  Magnetic nanoparticles for imaging dendritic cells.

Authors:  Saho Kobukai; Richard Baheza; Jared G Cobb; Jack Virostko; Jingping Xie; Amelie Gillman; Dmitry Koktysh; Denny Kerns; Mark Does; John C Gore; Wellington Pham
Journal:  Magn Reson Med       Date:  2010-05       Impact factor: 4.668

Review 4.  Magnetic nanoparticles for cancer diagnosis and therapy.

Authors:  Mehmet V Yigit; Anna Moore; Zdravka Medarova
Journal:  Pharm Res       Date:  2012-01-25       Impact factor: 4.200

Review 5.  The evolution of imaging in cancer: current state and future challenges.

Authors:  Luke J Higgins; Martin G Pomper
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 6.  Noninvasive cell-tracking methods.

Authors:  Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

7.  Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

Authors:  Juan Fu; Ian-James Malm; Deepak K Kadayakkara; Hy Levitsky; Drew Pardoll; Young J Kim
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

Review 8.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

Review 9.  Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma models.

Authors:  Bin Wang; Chong Sun; Sijia Wang; Na Shang; Matteo Figini; Quanhong Ma; Shanzhi Gu; Daniele Procissi; Vahid Yaghmai; Guoxin Li; Andrew Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

Review 10.  In vivo MRI cell tracking: clinical studies.

Authors:  Jeff W M Bulte
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.